| Literature DB >> 22054892 |
Anil Vachani1, Edmund Moon, Elliot Wakeam, Andrew R Haas, Daniel H Sterman, Steven M Albelda.
Abstract
Both advanced-stage lung cancer and malignant pleural mesothelioma are associated with a poor prognosis. Advances in treatment regimens for both diseases have had only a modest effect on their progressive course. Gene therapy for thoracic malignancies represents a novel therapeutic approach and has been evaluated in several clinical trials. Strategies have included induction of apoptosis, tumor suppressor gene replacement, suicide gene expression, cytokine-based therapy, various vaccination approaches, and adoptive transfer of modified immune cells. This review considers the clinical results, limitations, and future directions of gene therapy trials for thoracic malignancies. Copyright ÂEntities:
Mesh:
Year: 2011 PMID: 22054892 PMCID: PMC3210443 DOI: 10.1016/j.ccm.2011.08.006
Source DB: PubMed Journal: Clin Chest Med ISSN: 0272-5231 Impact factor: 2.878